Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could flickering lights and tones boost brain function in Alzheimer's?

NCT ID NCT05206305

Symptom relief Sponsor: University of Tennessee Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a headset that delivers flashing lights and clicking sounds at 40 times per second (40 Hz) for one hour daily. Researchers want to see if this stimulation improves visual processing and thinking in 20 people aged 60+ with Alzheimer's disease. Participants will have brain wave tests and thinking assessments before and after 8 weeks of use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GammaSense Stimulation device (non-invasive light and sound stimulation at 40 Hz)
What this could lead to
If it works, this could point toward a drug-free way to ease cognitive symptoms in Alzheimer's disease.
What could go wrong
This is a very small early study with only 20 people, so results may not apply widely. The device is not a cure and may have no lasting benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011) * Fluent and literate in English language * Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research * Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results Exclusion Criteria: * Not fluent and literate in English * Severe dementia * Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities * Cardiac pacemakers or any other implants that may not be compatible with MRI * Cognitively impaired to the point the patient is unable to consent for themselves * Claustrophobic to the point that medication is required

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease

Contacts and locations

Locations

  • University of Tennessee Medical Center

    Knoxville, Tennessee, 37920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.